Home > Resources > Whitepapers > A roadmap for Glycoscience in Europe

A roadmap for Glycoscience in Europe

Glycoscience is the science and technology of carbohydrates (also known as sugars or saccharides), which are the most abundant biological molecules on Earth and make up part of the biology of all living organisms. By producing carbohydrates from sunlight and carbon dioxide, plants, algae and some photosynthetic bacteria create the renewable biomass, generating an economically viable and sustainable alternative to fossil resources. Using carbohydrates instead of oil, gas and coal for energy and as raw materials will reduce carbon footprints and help to address one of the most important challenges to the European Bioeconomy and to society – achieving economic growth without damage to the environment.

Spotlight

Luma Healthcare, Inc.

Luma Healthcare was born out of the fact that no single source existed to go and get healthy. Our founders, whose backgrounds included Medicine, Clinical Research, Law, and Venture Capital, decided to rethink the problems of modern day Primary and Secondary Care, with the Patient As The Beneficiary. The result was the creation of Luma Healthcare, Inc. a healthcare technology - patient centric - platform.

OTHER WHITEPAPERS

Considerations for migrating a drug product presentation from vial to pre-filled syringe

whitePaper | December 9, 2022

There is an upward trend for pharmaceutical companies to ask their contract development and manufacturing organisations (CDMO).

bFGF Supports Human ES Cell Self-Renewal

whitePaper | March 24, 2023

Basic fibroblast growth factor (bFGF) is an important cytokine used to support the growth and self renewal of human embryonic stem cells.

THE RNA PLATFORM

whitePaper | May 26, 2022

Exploring biomarkers with the new central dogma. It can be a daunting decision for scientists to know when to focus on DNA, messenger RNA (mRNA), non-coding RNA (ncRNA) or protein biomarkers for routine clinical use, with each exhibiting its own strengths and limitations

Application of Single-Use Technologies(SUT) in Biosimilar Development

whitePaper | December 20, 2022

The current processing paradigm of large manufacturing facilities dedicated to singleproduct production is no longer an effective approach for best manufacturing practices.

Small Molecule Apis Made with Compelling Science

whitePaper | July 17, 2023

As your API demand grows, we grow with you. While we can manufacture volumes in metric tons, we can also go small. If you have a chemistry-based compound and need smaller batches for clinical or commercial use, we can offer the quantities you need at our cGMP small-scale/pilot facilities until you’re ready for full-scale manufacturing.

More Whitepapers